General features of patients with Pulmonary Langerhans Cell Histiocytosis followed in our instution

Basit Öğe Kaydı
dc.authoridCETINKAYA, ERDOGAN/0000-0002-0891-0020
dc.authoridDemirkol, Baris/0000-0001-5585-3842
dc.contributor.authorAcat, Murat
dc.contributor.authorTanriverdi, Elif
dc.contributor.authorUgur Chousein, Efsun Gonca
dc.contributor.authorDemirkol, Baris
dc.contributor.authorYildirim, Binnaz Zeynep
dc.contributor.authorTuran, Demet
dc.contributor.authorOzgul, Mehmet Akif
dc.date.accessioned2024-09-29T16:09:56Z
dc.date.available2024-09-29T16:09:56Z
dc.date.issued2018
dc.departmentKarabük Üniversitesien_US
dc.description.abstractIntroduction: Pulmonary Langerhans Cell Histiocytosis (PLCH) is a rare disease affecting young smokers. It is more common between the ages of 20-40 and equals the male/female ratio. Lung biopsy is the most useful methods for diagnosis. The first treatment is to quit smoking. Corticosteroids or chemotherapeutic agents can be used in severe progressive cases despite of quiting smoking. The patients with PLCH followed in our clinic were assessed with general clinical features in the light of the literature. Materials and Methods: We retrospectively evaluated patients with PLCH in our clinic between January 1999 and June 2017. Results: The female and male distribution of the 21 patients was 11/10. The average age was 35.04 +/- 11.78 years. All patients were active smokers at the time of admission. The most common symptom was dyspnea. The most common finding in the pulmonary function tests was obstructive ventilatory defect. The DLCO value of the 70% patient in the carbonmonooxid diffusion test was below 80%. The most common pathologic findings detected in high-resolution chest tomography (HRCT) were cystic lesions involving bilateral upper and middle areas. There were 3 (14%) patients with pneumothorax at the time of admission and 6 (28.5%) patients with pneumothorax history before. The most common diagnostic method was open lung biopsy. All the patients quit cigarette after the diagnosis. There were 6 patients using steroid therapy, 1 patient receiving steroid and bosentan therapy, and 1 patient made pleurectomy due to recurrent pneumothorax. Lung transplantation was done to patient who received combined bosentan treatment with steroids. Conclusion: PLCH is a rare disease and should be considered in young, smokers with spontaneous pneumothorax and cystic lung disease in the differential diagnosis. As more diffusions are affected in patients, respiratory functions for follow-up should be evaluated with diffusion tests. It is essential to quit smoking in therapy.en_US
dc.identifier.doi10.5578/tt.67334
dc.identifier.endpage211en_US
dc.identifier.issn0494-1373
dc.identifier.issue3en_US
dc.identifier.pmid30479227en_US
dc.identifier.scopus2-s2.0-85057182065en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage205en_US
dc.identifier.trdizinid300466en_US
dc.identifier.urihttps://doi.org/10.5578/tt.67334
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/300466
dc.identifier.urihttps://hdl.handle.net/20.500.14619/7852
dc.identifier.volume66en_US
dc.identifier.wosWOS:000448474100003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Assoc Tuberculosis & Thoraxen_US
dc.relation.ispartofTuberkuloz Ve Torak-Tuberculosis and Thoraxen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPulmonary Langerhans Cell Histiocytosisen_US
dc.subjectsmokingen_US
dc.subjectspontan pneumothoraxen_US
dc.titleGeneral features of patients with Pulmonary Langerhans Cell Histiocytosis followed in our instutionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize